Clavien-Dindo分级系统分析不同供肝类型肝移植患者术后早期并发症发生率比较研究*

doi:10.3969/j.issn.1672-5069.2023.05.034

实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (5): 738-741.doi: 10.3969/j.issn.1672-5069.2023.05.034

Clavien-Dindo分级系统分析不同供肝类型肝移植患者术后早期并发症发生率比较研究^*

张树庚, 张少博, 朱泽斌, 栗雪峰, 蔡伟, 郭亚飞, 刘连新

230036 合肥市中国科学技术大学附属第一医院/安徽省立医院肝胆外科器官移植中心

收稿日期:2023-06-06 出版日期:2023-09-10 发布日期:2023-09-13
通讯作者: 郭亚飞,E-mail:guoyafei_2008@163.com
作者简介:张树庚,男,39岁,医学博士,副主任医师。E-mail:shugeng517@163.com
基金资助:
^*安徽省自然科学基金资助项目(编号:2208085MH245)

Early post-operational complications in patients with orthotopic liver transplantation receiving different deceased donors

Zhang Shugeng, Zhang Shaobo, Zhu Zebin, et al

Centre of Hepatobiliary Surgery and Organ Transplantation, Anhui Provincial Hospital, First Affiliated Hospital, University of Science and Technology of China, HeFei 230036, Anhui Province, China

Received:2023-06-06 Online:2023-09-10 Published:2023-09-13

摘要/Abstract

摘要： 目的采用Clavien-Dindo分级系统分析接受不同供肝的原位肝移植受者发生早期并发症的差异。方法 2017年4月～2020年12月我中心诊治的60例终末期肝病患者,均接受公民逝世后器官捐献肝移植术治疗,其中接受脑死亡后捐献(DBD)27例,接受心脏死亡后捐献(DCD)26例和接受脑-心双死亡后捐献(DBCD)7例,均接受同种异体经典原位肝移植术。采用Clavien-Dindo分级系统对术后早期(1个月内)并发症进行分级,比较Ⅲ级及以上并发症发生率。结果在60例患者中,有16例(26.6%)发生了术后早期III级及以上的并发症,其中DBD组2例 (7.4%),DCD组2例 (7.7%),DBCD组2例 (28.6%);DBD组发生IV级并发症 1例 (3.7%),DCD组2例 (7.7%),DBCD组无(0.0%); DBD组发生V级并发症(死亡)3例 (11.1%),DCD组3例 (11.5%),DBCD组1例 (14.3%),三组并发症发生率比较,无显著性差异(P>0.05)。结论与标准的DBD供肝移植比,接受DCD或DBCD供肝移植也不增加术后早期并发症的发生。

关键词: 原位肝移植, 终末期肝病, 手术并发症, 死亡捐献, Clavien-Dindo分级, 治疗

Abstract: Objective The aim of this study was to investigate the incidences of early post-operational complications in patients with orthotopic liver transplantation (OLT) receiving different deceased donors. Methods 60 patients with end-stage liver diseases were encountered in our center between April 2017 to December 2020, and all underwent allogeneic classical OLT, receiving donation after brain death (BDB) in 27 cases, donation after cardiac death (DCD) in 26 cases and donation after brain death followed by cardiac death (DBCD) in 7 cases. The early (less than 1 month) postoperative complications was defined according to Clavien-Dindo classification, and the incidences of grade III and the above complications were compared among the three groups. Results Out of the 60 patients after OLT, the early postoperative complications of grade III or above occurred in 16 cases (26.6%), and in the grade III complications, there were 2 cases (7.4%) in DBD group, 2 cases (7.7%) in DCD group and 2 cases (28.6%) in DBCD group; as for the grade IV complications, there were 1 case (3.7%) in DBD group, 2 cases (7.7%) in DCD group, and no cases (0.0%) in DBCD group; in the grade V (death) complications, there were 3 cases (11.1%) in DBD group, 3 cases (11.5%) in DCD group, and 1 case (14.3%) in DBCD group, no significant differences as respect to the incidences of complications among the three groups (P>0.05). Conclusion Compared with the standard DBD donor liver, the patients receiving liver from DCD donor or from DBCD donor do not increase the incidence of early postoperative complications.

Key words: Orthotopic liver transplantation, End-stage liver disease, Surgical complications, Deceased donors, Clavien-Dindo classification, Therapy

张树庚, 张少博, 朱泽斌, 栗雪峰, 蔡伟, 郭亚飞, 刘连新. Clavien-Dindo分级系统分析不同供肝类型肝移植患者术后早期并发症发生率比较研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 738-741.

Zhang Shugeng, Zhang Shaobo, Zhu Zebin, et al. Early post-operational complications in patients with orthotopic liver transplantation receiving different deceased donors[J]. Journal of Practical Hepatology, 2023, 26(5): 738-741.

参考文献

[1] Wilke TJ, Fremming BA, Brown BA, et al. 2020clinical update in liver transplantation. J Cardiothorac Vasc Anesth,2022,36(5):1449-1457.
[2] 段鑫,郑树森.心脏死亡器官捐献供肝质量评估进展.中华移植杂志(电子版),2015,9(1):40-43.
[3] Besch C, Michard B, Addeo P, et al. Impact of early remote organ dysfunction on long-term survival after liver transplantation. Clin Res Hepatol Gastroenterol, 2019, 43(6):730-737.
[4] 宗金娟,周明,史家乐.应用CTA技术和超声评估肝移植术患者术前肝脏血供状态研究.实用肝脏病杂志,2022,25(4):583-586.
[5] Wilson GC, Hoehn RS, Ertel AE, et al. Variation by center and economic burden of readmissions after liver transplantation. Liver Transpl,2015,21(7):953-960.
[6] Amara D, Parekh J, Sudan D, et al. Surgical complications after living and deceased donor liver transplant: the NSQIP transplant experience. Clin Transplant, 2022,36(6):e14610.
[7] 孙煦勇,秦科.中国公民逝世后捐献供器官功能评估和维护专家共识(2016年版).中华移植杂志(电子版),2016,10(4):145-153.
[8] Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg,2009,250(2):187-196.
[9] Starzl TE, Marchioro TL, Porter KA, et al. Homotransplantation of the liver. Transplantation,1967,5(4):790-803.
[10] Guo Y, Zhu Z, Wu W, et al. Liver transplantation in a patient with acute-on-chronic liver failure due to traditional Chinese medicine intoxication using donation after circulatory death from a renal transplant recipient: a case report. Transplant Proc,2020,52(9):2813-2816.
[11] Ozturk NB, Muhammad H, Gurakar M, et al. Liver transplantation in developing countries. Hepatol Forum,2022,3(3):103-107.
[12] Dutkowski P, Schlegel A, Slankamenac K, et al. The use of fatty liver grafts in modern allocation systems: risk assessment by the balance of risk (BAR) score. Ann Surg,2012,256(5):861-869.
[13] Moosburner S, Sauer IM, Förster F, et al. Early allograft dysfunction increases hospital associated costs after liver transplantation-a propensity score-matched analysis. Hepatol Commun,2020,5(3):526-537.
[14] Olthoff KM, Kulik L, Samstein B, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl,2010,16(8):943-949.
[15] Hirao H, Nakamura K, Kupiec-Weglinski JW. Liver ischaemia-reperfusion injury: a new understanding of the role of innate immunity. Nat Rev Gastroenterol Hepatol,2022,19(4):239-256.
[16] Huang J. The "Chinese mode" of organ donation and transplantation. Hepatobiliary Surg Nutr,2017,6(4):212-214.
[17] 邹晓明,云哲琳,张生彬,等.胰十二指肠切除术后并发症的Clavien-Dindo分级及危险因素分析. 中华消化外科杂志,2016,15(6):579-583.
[18] Sneiders D, Houwen T, Pengel LHM, et al. Systematic review and meta-analysis of posttransplant hepatic artery and biliary complications in patients treated with transarterial chemoembolization before liver transplantation. Transplantation,2018,102(1):88-96.
[19] Guo Y, Wang J, Wu W, et al. Incidence of ischemia reperfusion injury related biliary complications in liver transplantation: effect of different types of donors. Transplant Proc,2022,54(7):1865-1873.
[20] Raghuram A, Restrepo A, Safadjou S, et al. Invasive fungal infections following liver transplantation: incidence, risk factors, survival, and impact of fluconazole-resistant candida parapsilosis (2003-2007). Liver Transpl,2012,18(9):1100-1109.
[21] Salviano MEM, Lima AS, Tonelli IS, et al. Primary liver graft dysfunction and non-function: integrative literature review. Rev Col Bras Cir,2019,46(1):e2039.

Clavien-Dindo分级系统分析不同供肝类型肝移植患者术后早期并发症发生率比较研究^*

Early post-operational complications in patients with orthotopic liver transplantation receiving different deceased donors

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	盛秋菊, 窦晓光. 慢性HBV感染不同疾病状态治疗策略选择与获益评价[J]. 实用肝脏病杂志, 2023, 26(5): 609-611.
[2]	张丹, 丁洋. 慢性乙型肝炎患者病毒载量与疾病状态和治疗策略选择^*[J]. 实用肝脏病杂志, 2023, 26(5): 612-614.
[3]	彭真, 宁会彬, 李宽, 尚佳. HBeAg阳性慢性HBV 感染分期和治疗新进展[J]. 实用肝脏病杂志, 2023, 26(5): 615-617.
[4]	吴育龙, 庄见齐, 刘志成, 马侠槟. 核苷(酸)类似物治疗慢性乙型肝炎患者血清HBV pgRNA变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(5): 622-625.
[5]	王一卓, 张崴琪, 李红. 聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎患者3年随访研究[J]. 实用肝脏病杂志, 2023, 26(5): 626-629.
[6]	李亚玲, 杨发成, 蒋亚西. 直接抗病毒药物治疗慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 638-641.
[7]	蔡涛, 魏玮, 王欣雯, 王玥坤, 秦军, 蓝晓红. 直接抗病毒药物治疗慢性终末期肾病合并慢性丙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 642-645.
[8]	罗良德, 苏建明, 任成果, 申红. 复方甘草酸苷联合非诺贝特治疗代谢相关性脂肪性肝病患者疗效及其对脂代谢的影响^*[J]. 实用肝脏病杂志, 2023, 26(5): 650-653.
[9]	莫俊俏, 林景, 羊莉. 水飞蓟宾胶囊联合多烯磷脂酰胆碱治疗抗结核药物所致药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 666-669.
[10]	武向慧, 李龙虎, 景斐华, 武鹏. 经导管动脉化疗栓塞联合射频消融治疗肝细胞癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 702-705.
[11]	陈长广, 肖荣, 王俊. DEB-TACE序贯射频消融治疗原发性肝癌患者效果研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 706-709.
[12]	叶超荣, 张涛, 吴永军, 利民. LCBDE与ERCP术治疗胆总管结石患者效果研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 742-745.
[13]	宋巍, 李智德, 李玉鹏, 陈雄. 吲哚菁绿荧光显像指导腹腔镜胆囊切除术治疗胆囊良性疾病患者效果研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 746-749.
[14]	黄龙, 范雅茜, 段钟平. 舒肝宁注射液利胆退黄抗炎护肝机制研究进展^*[J]. 实用肝脏病杂志, 2023, 26(5): 765-768.
[15]	杨凯, 张凯, 汪勇. 应用聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎患者血清sVAP-1和SAA水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(4): 484-487.